Payment overview · 2025
General Payments
$966.22
56 reported records · 15 companies
Healthcare provider profile · identity verified
Bruce W Lee, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CHANUTE, KS · NPI 1952391740
Verified facts
What the public records show
CMS Open Payments records show Bruce W Lee, D.O. received $966.22 in general payments during 2025 across 56 reported records.
ABBVIE INC. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $205.95 | 21.3% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $195.39 | 20.2% | 9 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $110.97 | 11.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $104.91 | 10.9% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $93.36 | 9.7% | 6 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $42.83 | 4.4% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $37.56 | 3.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.77 | 3.6% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.74 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.93 | 3.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.92 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.79 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.70 | 1.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.63 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.77 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $966.22 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $144.73 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $114.60 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $110.97 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $104.91 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $104.91 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $80.79 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $63.70 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.70 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.22 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.22 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.15 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $42.83 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $42.83 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $37.56 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $37.56 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 213 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 743 | 160 |
| Lisinopril | Lisinopril | 604 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 112 |
| Losartan Potassium | Losartan Potassium | 448 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 78 |
| Gabapentin | Gabapentin | 349 | 67 |
| Furosemide | Furosemide | 318 | 73 |
| Omeprazole | Omeprazole | 316 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 69 |
| Potassium Chloride | Potassium Chloride | 287 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 278 | 60 |
| Tramadol Hcl | Tramadol Hcl | 271 | 54 |
| Metformin Hcl Er | Metformin Hcl | 268 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 242 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 58 |
| Spironolactone | Spironolactone | 233 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 229 | 29 |
| Eliquis | Apixaban | 213 | 32 |
| Sertraline Hcl | Sertraline Hcl | 193 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 46 |
| Simvastatin | Simvastatin | 186 | 42 |
| Metformin Hcl | Metformin Hcl | 175 | 41 |
| Carvedilol | Carvedilol | 169 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 51 |
| Clonidine Hcl | Clonidine Hcl | 158 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 157 | 33 |
| Donepezil Hcl | Donepezil Hcl | 153 | 24 |
| Warfarin Sodium | Warfarin Sodium | 143 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 31 |
| Glimepiride | Glimepiride | 138 | 29 |
| Januvia | Sitagliptin Phosphate | 128 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 125 | 33 |
| Fentanyl | Fentanyl | 123 | 15 |
| Clonazepam | Clonazepam | 120 | 18 |
| Ozempic | Semaglutide | 119 | 17 |
| Montelukast Sodium | Montelukast Sodium | 116 | 23 |
| Prednisone | Prednisone | 116 | 60 |
| Trazodone Hcl | Trazodone Hcl | 114 | 19 |
| Atenolol | Atenolol | 112 | 22 |
| Ezetimibe | Ezetimibe | 112 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 101 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 25 |
| Farxiga | Dapagliflozin Propanediol | 98 | 16 |
| Lovastatin | Lovastatin | 97 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 21 |
| Lorazepam | Lorazepam | 94 | 20 |
| Bupropion Xl | Bupropion Hcl | 93 | 24 |
| Famotidine | Famotidine | 93 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 84 | 20 |
| Xarelto | Rivaroxaban | 84 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 19 |
| Digoxin | Digoxin | 80 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 76 | 23 |
| Alprazolam | Alprazolam | 75 | 18 |
| Allopurinol | Allopurinol | 73 | 12 |
| Myrbetriq | Mirabegron | 71 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 16 |
| Bumetanide | Bumetanide | 66 | 16 |
| Cimetidine | Cimetidine | 66 | suppressed |
| Meloxicam | Meloxicam | 64 | 16 |
| Mirtazapine | Mirtazapine | 64 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 12 |
| Pregabalin | Pregabalin | 63 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 62 | 16 |
| Primidone | Primidone | 62 | 11 |
| Propranolol Hcl | Propranolol Hcl | 60 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 57 | suppressed |
| Cephalexin | Cephalexin | 53 | 47 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 15 |
| Buspirone Hcl | Buspirone Hcl | 49 | 11 |
| Bupropion Hcl | Bupropion Hcl | 48 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Celecoxib | Celecoxib | 44 | suppressed |
| Lactulose | Lactulose | 43 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 28 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 17 |
| Finasteride | Finasteride | 34 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 34 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 23 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 19 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Dayvigo | Lemborexant | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $966.22 · 56 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, BEXSERO, BEYFORTUS, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Fluad, Flucelvax, GVOKE HYPOPEN, NURTEC ODT, OTEZLA, Ozempic, PEDIARIX, PENMENVY, PREVNAR 20, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error